CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted...
LONDON, UNITED KINGDOM, June 9, 2025 /EINPresswire.com/ -- The Principality of Liechtenstein continues to demonstrate its exceptional standing on the global stage, with two recent developments underscoring its strength in both financial...
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*)...
Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 MAESTRO-NASH trial demonstrating Rezdiffra reduced...
Press Release 4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion Araris will receive USD 400 million upfront, with the potential for additional near-term and long-term milestone payments...
His Serene Highness Hereditary Prince Alois Philipp Maria of the Principality of Liechtenstein will make a working visit to Singapore from 1 November to 4 November 2024. During the visit, HSH Hereditary Prince Alois will meet President Tharman...
Westford, USA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Dental Equipment Market size was valued at USD 6.79 billion in 2023 to USD 10.90 billion by 2031, growing at a CAGR of 6.10% during the forecast period (2024-2031). The tools that are utilized for...
Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity EC approval follows positive CHMP opinion, MHRA conditional marketing...
VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest study of CIDP patients to date First...
Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progression Duvyzat is an orally administered treatment for DMD in patients 6 years and older who are able to walk The...
What drugs does the Food and Drug Administration (FDA) block patients and doctors from accessing that Canadian patients and doctors can get? To address the question, we compared the contents of the American Drugs@FDA database and the Canadian Drug...
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are wafting across the Pharmalot campus, where the official mascots are foraging for their breakfast and rousing the neighbors. This means we are free to focus...
Montreal, Canada-based ExCellThera, a company specializing in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex Biologics, announced on Aug. 27, 2025 that it has received conditional marketing authorization by...
Thank you for your interest in the webinar! Check your inbox for an email with instructions on viewing this on-demand presentation. Oops something went wrong. Watch Now {"LSQLeadFields":[{"Seq":1,"Name":"First...
Stem cell transplants that are a standard treatment for certain blood cancers are out of reach for many patients. The procedure requires cells from a matched donor, but a match isn’t always available. A new cell therapy derived from umbilical cord...
Last Thursday, Aug. 21, the Colorado General Assembly reconvened for its 2025 Extraordinary Session, mostly focused on addressing the $750‒$800 million state budget shortfall created by the federal government’s passage of the One Big Beautiful...
ExCellThera has announced that the European Commission (EC) has granted conditional marketing authorisation for its Zemcelpro cell therapy to treat blood cancer patients without access to suitable donor cells. The approval was granted to the...
Gilead Sciences, Inc., a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced that the European Commission (EC) has granted marketing authorization for Yeytuo (lenacapavir)—the...
Alvotech, a global biotech company, and Advanz Pharma Holdco Limited (Advanz Pharma), a UK-headquartered global pharmaceutical company, announced that the European Commission has approved Mynzepli as a biosimilar to Eylea (aflibercept), in a...
Madrigal Pharmaceuticals Inc, a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced that the European Commission (EC) has granted conditional marketing...
